Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125-Reference-Cited by-同舟云学术

Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125

Published:2021-11 Issue: Volume:38 Page:100847
ISSN:2352-5789
Container-title:Gynecologic Oncology Reports
language:en
Short-container-title:Gynecologic Oncology Reports

Author:

Minato Takamichi,Ito Shin,Li Bin,Fujimori Haruna,Mochizuki Mai,Yamaguchi Kazunori,Tamai Keiichi,Shimada Muneaki,Tokunaga Hideki,Shigeta Shogo,Sato Ikuro,Shima Hiroshi,Yamada Hidekazu,Yaegashi Nobuo,Yasuda Jun

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference38 articles.

1. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023

2. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype;Coburn;Int. J. Cancer,2017

3. Ovarian cancer statistics, 2018;Torre;CA Cancer J. Clin.,2018

4. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer;Bowtell;Nat. Rev. Cancer,2015

5. Nagase S, Ohta T, Takahashi F, Yaegashi N, Board members of the 2020 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2017 and annual treatment report for 2012 J. Obstet. Gynaecol. Res. 2021; 47: 1631–1642. 10.1111/jog.14724.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities;Exploration of Targeted Anti-tumor Therapy;2024-06-19

2. Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial;Translational Oncology;2024-05

3. Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis;International Journal of Gynecologic Cancer;2024-04-23

4. Sensitive circulating tumor DNA–based residual disease detection in epithelial ovarian cancer;Life Science Alliance;2024-04-05

5. The Significance and Importance of dPCR, qPCR, and SYBR Green PCR Kit in the Detection of Numerous Diseases;Current Pharmaceutical Design;2024-01